APIFARMA PORTUGUESE PHARMACEUTICAL INDUSTRY ASSOCIATION

Similar documents
Organizing committee at imed.ulisboa/ffulisboa Joao Goncalves (Coordinator) and Paula Brito.

The Belgian pharmaceutical industry strengthens its leading European position. Belgian pharma figures 2015, in a European perspective

Università Cattolica del Sacro Cuore

Global Forum on Competition

Pharmamarketing - strategic challenges

Section I: Pharmaceuticals and Medical Devices

Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products

Updated EU Medical Device Regula2ons: What s In, What s Out, and What s Hot?

The European Medical Technology Industry. in figures / 2018

Contact Information: Rapture Biotech D-201, Sector - 10, Noida Uttar Pradesh. Phone , ,

Establishment of Clinical Trial Infrastructure

REIMAGINING DRUG DEVELOPMENT:

-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009

AGENDA Closing the regulatory cycle: effective ex post evaluation for improved policy outcomes

The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective

Course ADVANCED DRUG DELIVERY July 03-07, 2017 Faculty of Pharmacy Amphitheatre B Universidade de Lisboa, Portugal

Sector: The Pharmaceutical and Healthcare. Keywords: Bulgaria, Sofia, Pharmaceutical sector

January, Antares Consulting Corporate presentation

Using local RWD to drive global therapeutic advancements.

Pharma R&D and Patents support Health Care & Economy

EUnetHTA. European network for Health Technology Assessment. European network for Health Technology Assessment JA

WORKSHOP ON NUCLEAR MOLECULAR IMAGING

BIOTECH IN FRANCE. key info in. points

EU health policy. Strategy for the pharmaceutical industry and biosimilars. Salvatore D'Acunto. DG Research. DG Internal Market. DG Health & Consumers

Regulatory system strengthening

International Transfers of Personal Data at sanofi-aventis R & D

The overview of Estonian biotechnology sector (2012)

EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria

Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS

YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.

Workshop on Access to and Uptake of Biosimilar Medicinal Products

MARKETS & CUSTOMERS. Progressing globalization. Evolving markets

Overview of IMV Data: Perspectives on Large Scale Data Collection. December 8, 2011

Baek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety

A Physician s consideration towards Biosimilars. João Eurico Fonseca

Comments from the FDA Working Group on SUBGROUP ANALYSES. Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics

378/2007 Coll. ACT of 6 December 2007 on Pharmaceuticals and on Amendments to Some Related Acts (the Act on Pharmaceuticals)

Rare diseases in the 7th EU Framework Programme for Research and Technological Development

Summary of Medicines Plan

State Control of Medicines and Medical Devices in Russian Federation

Myeloma UK Policy Working with the Pharmaceutical Industry

Program of study. pharmacy. 1st year

Trust Board Meeting: Tuesday, 12 February 2013 TB Quarterly HR and Workforce Report. A paper for information and discussion

DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective

Partnering with Rare Disease Patient Groups. Namrata Taak R&D External Communications, Rare Diseases

Do We Need Medical Affairs?

Bayer Corporate Policy: Global Publications Deriving from Clinical Studies in Humans

Clinical Trials application process, legislation & guidelines

NATIONAL COUNCIL OF ETHICS FOR THE LIFE SCIENCES Presidency of the Council of Ministers 56/CNECV/08

GS1 Healthcare Newsletter

Panel Discussion MINI SUMMIT XIII: global fair market value update

Taking a Leap Toward Global Supply Chain Efficiency - Part II

VALUE-BASED HEALTHCARE A MANUFACTURER S PERSPECTIVE PETER JUHN, MD, MPH VICE PRESIDENT AND GLOBAL HEAD, VALUE-BASED PARTNERSHIPS

Agenzia Italiana del Farmaco

Cardinal Health overview and strategic priorities

OVERVIEW. ibet MISSION AND OBJECTIVES

Guide to Wholesaling and Brokering of Medicinal Products for Human Use in Ireland

STATE OF THE ASIA-PACIFIC PHARMACEUTICAL INDUSTRY 2013: EXECUTIVE SUMMARY

HEALTHCARE. Software Solutions for Hospitals, Laboratories and other Healthcare Institutions. koraka

Optum Performance Analytics

Rare Diseases: Challenges and Opportunities NIH Perspective

KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar

SUCCESSFUL BRANDS: LATVIA ESTONIA CROATIA GERMANY UNITED KINGDOM BOSNIA-HERZEGOVINA BULGARIA MACEDONIA SERBIA CZECH REPUBLIC SLOVAKIA FRANCE AUSTRIA

Sponsorship of Clinical Research Studies

Research and development case study. Human health research

Hannover, your first foothold for business expansion into Europe

Type of Activity. Universal Activity Number L04-P

Wednesday October 14, Invitation only. For more information, please visit

Pharmaco-Epidemiological Studies. A French experience

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

The Drug Importation Debate: An Economic Perspective

AFSSAPS : Inclusion of external experts into the review process

SMEs in IMI2 Calls for Proposals

An Act respecting the Institut national d excellence en santé et en services sociaux

Sirtex Medical Limited

The European Medical Technology Industry in figures

Shifting Pharma Sales Models. Text for a pull out can go heretext for a pull out can go heretext for a pull out can go

EU Regulation Review: challenges and opportunities for industry

AN UPDATE ON INDIAN BIOSAFETY REGULATORY SYSTEM. Dr. Vibha Ahuja Biotech Consortium India Limited

Regulatory Pathways for Rare Diseases

Di Renzo Regulatory Affairs ROME - MILAN - LONDON

VENDORS GUIDE TO DOING BUSINESS PENN STATE MILTON S. HERSHEY MEDICAL CENTER AND PENN STATE COLLEGE OF MEDICINE

Making the entire pharmaceutical chain sustainable. Bengt Mattson. Policy Manager, LIF (Manager,CSR & Environmental Affairs, Pfizer AB)

European Medicines Agency re-organisation

Department At-A-Glance

INFECTIOUS DISEASES WE ARE LEADING THE WAY.

Nanotechnology and Advanced Materials for more effective Healthcare

Dr. Abdulrahman Mohammad Al Jassmi Chief Executive Officer Dubai Hospital Dubai Health Authority

Greenwood Genetic Center

Pharma Medical Affairs 2020 and beyond. Matthias Evers Edd Fleming Arnab Ghatak Jan Hartmann Arif Nathoo Ron Piervincenzi Lawrence Wai Ann Westra

CHAPTER 2 PHARMACEUTICAL LAWS AND REGULATIONS 1. PHARMACEUTICAL LAWS 2. PHARMACEUTICAL AND MEDICAL DEVICE ACT

Communicating Emerging Drug Therapies Prior to FDA Approval. May 4, 2017

Report from the Paediatric Committee on its first anniversary

US FDA: CMC Issues for INDs

6. Vision 3: Leading the Japanese economy forward as a high value-added industry"

Importance of Pharmacovigilance for Pharmaceutical Industry

Transcription:

APIFARMA PORTUGUESE PHARMACEUTICAL INDUSTRY ASSOCIATION 2017

ABOUT US Portuguese Pharmaceutical Industry Association Founded in 1975, succeeds the National Guild of the Manufacturers of Medicinal Products (1939) 75 years of activity Represents about 120 companies It is the only Association in Europe that brings together Human Health OTC (non prescription medicines) In Vitro Diagnostics Vaccines Prescription medicines Animal Health Generics

OUR MISSION Contribute for the socioeconomic development of the Pharmaceutical Sector and for the country Contribute for the improvement of health in Portugal Contribute to facilitate patient access to new therapies Defend the common interests of its members

Protect the quality, safety and efficacy of medicines Promote an efficient medicines approval system Protect the industrial property rights Promote proximity with the patient OBJECTIVES Use the knowledge and the scientific patrimony in the relationship with the scientific community Promote public health and environment Promote proximity with the Community to make clear its mission and values

INTERNAL STAFF GENERAL ASSEMBLY PRESIDENT João Almeida Lopes GENERAL COUNCIL FISCAL COUNCIL MEDIA ADVISORY BOARD F5C SPECIALISED COMMITTEES APIFARMA OTC, APIFARMA VET, CEB, CEMD, CEV BOARD DEPUTY Miguel Ginestal EXECUTIVE DIRECTOR Heitor Costa EXECUTIVE SECRETARIAT Susana Godinho Miguel Fragoso ADMINISTRATION João Teles WORKING GROUPS ACCESS, AMBULATORY, HOSPITAL AFFARIS, COMPLIANCE, CLINICAL RESEARCH ACCOUNTING Helena Teixeira TECHNICAL AFFARIS Cristina Lopes (Dir.) Paula Costa Gomes Alexandra Gonçalves LEGAL AFFAiRS Pedro Caridade de Freitas (Dir.) Carolina Dias Ferreira DATA AND ANALYSIS Paula Costa (Coord.) COMMUNICATION, INFORMATION AND EXTERNAL AFFAIRS Isabel Soares TECHNICAL AND INSTITUTIONAL AFFAIRS Manuela Mendonça RECEPTION Natércia Barreto Sandra Tavares

EXPERTISE AREAS Technical Affairs Provision of services in economic, financial, pharmaceutical and professional training Legal Affairs Provision of services in the area of pharmaceu cal legisla on, corporate, labour, administrative and ethical Communication and External Affairs Promote the image and position of the Pharmaceutical Industry among the media, patients associations, opinion leaders and general public Data & Analysis Analysis and production of information and studies in the context of the Pharmaceutical Industry

SPECIALISED COMMITTEES Given the diversity of interests represented by our Association, we have 6 specialised committees: Vaccines (CEV) OTC (APIFARMA OTC) In vitro Diagnostics (CEMD) Animal Health (APIFARMA VET) Biotechnology (CEB)

WORKING GROUPS Clinical Research Access to Medicines Compliance Hospital Affairs Ambulatory Care

11 Companies PharmaPortugal

NATIONAL INSTITUTIONAL RELATIONS Government Ministry of Health Ministry of Economics Ministry of Finance Ministry of Labour DG Health DG Economic Activities National Assembly / Parliamentary Groups Parliamentary Committees on Health, Economic Affairs, Innovation and Regional Development National Authority INFARMED Professional Associations Medical Association Veterinary Medical Association Dentist Association Pharmaceutical Association Portuguese Association of Generic Drugs (APOGEN) Confederation of Portuguese Industry (CIP) Portuguese Industrial Association (AIP) National Industrial Property Institute (INPI) National Association of Pharmacies ANF Patient Organizations

INTERNATIONAL INSTITUTIONAL RELATIONS EFPIA (European) Medicines IFPMA (Worldwide) Medicines AESGP (European) OTC Medicines MedTech Europe Medical Technology Industry IFAH Europe Animal Health Counterpart Organisations European Political Institutions

THE PHARMACEUTICAL INDUSTRY IN PORTUGAL MEMBER COMPANIES 121 (Source: APIFARMA; Year:2017) AREAS OF INTERVENTION Innovative medicines; Generic medicines; OTC medicines; Biotechnology; Vaccines; In vitro diagnostics; Veterinary medicines; Research and clinical trials OUTPATIENT MARKET 1.900 million euro (Ex factory price; Year: 2016) => (2016/2015= 1,7%) 255,8 million packs (Year: 2016) (Source: IMS Health; Infarmed) HOSPITAL MARKET 1.107,2 million euro => (2016/2015= 7,5%) INVESTMENT IN R&D 75,1 million euro 7,2% of the total private investment in R&D (Source: INFARMED; Year: 2016) EMPLOYMENT 7.500 employees (Source: MCTES / IPCTN14; Year: 2014) (Source: APIFARMA associates; Jan.2016) PRODUCTION 1.490 million euro => (2015/2014= + 3,9%) (Source: INE; Year: 2015) EXPORTS 920 million euro => (2014/2013= + 4,9%) (Source: INE; Year: 2015)

PHARMACEUTICAL INDUSTRY IN FIGURES 1. Main Economic Indicators 2. Main Demographic Indicators 3. Healthcare Indicators 4. Pharmaceutical Sector Data 5. Pharmaceutical Market Medicines For Human Use 6. NHS Expenditure 7. Self Medication Market 8. Clinical Trials 9. In vitro Diagnostic Medical Devices Market 10. Animal Health Market

APIFARMA PORTUGUESE PHARMACEUTICAL INDUSTRY ASSOCIATION Rua Pêro da Covilhã, 22 1400 297 Lisboa Portugal T. 213 005 080 E. board@apifarma.pt I. www.apifarma.pt Thank you for your interest in APIFARMA and the Pharmaceutical Industry in Portugal. For more information, please reach us through the contacts above.